NovioSense Announces Positive Phase 2 Clinical Trial Results and the Commencement of a Second Follow Up Study
25.10.2018 17:03:00 EEST | Business Wire | Press release
NovioSense BV, the venture capital-backed clinical stage medical device company, today announced positive data from its NLNSGS2017-02 Phase 2 tear glucose sensor study. The NovioSense Glucose Sensor is a device that, when placed in the lower eyelid, continuously measures glucose levels in the tear fluid of diabetic patients. The results of the six-patient clinical trial are presented in the American Chemical Society Journal Biomacromolecules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181025005032/en/
NovioSense non-invasive tear glucose sensor (Photo: Business Wire)
Dr. Wilson, NovioSense’s CEO, said, “Today marks an important step in our tear glucose program. We opted to deploy the tear glucose sensor in diabetic patients to obtain evidence that tear glucose levels may be utilised to predict blood glucose levels with a clinically acceptable accuracy. These positive results from our phase 2 study demonstrate that the NovioSense Glucose Sensor can be used to measure glucose non-invasively in tears and correlates to blood glucose levels with an accuracy comparable to commercial, minimally invasive devices.”
The completed Phase 2 study in six diabetic patients was initiated based on positive results from a Phase 1 pilot safety study in 6 healthy subjects. On October 18, 2018 NovioSense initiated a follow-on study, NLNSGS2018-02, in 24 diabetic patients to gather additional evidence for the use of its sensor platform for diabetic patients.
Linze Dijkstra, Managing Partner of Health Innovations, said, “We invested in NovioSense in 2012 based on positive pre-clinical data and are delighted to see year-on-year progress in the development of this disruptive diagnostic platform.”
NovioSense BV has developed a flexible miniature sensor that, when placed in the lower eyelid, provides glucose measurements directly to a smartphone. NovioSense delivers the first of its kind eye-wearable, wireless, battery-free glucose sensor to provide pain-free, continuous glucose monitoring to all individuals with diabetes at an affordable price. The non-invasive sensor platform, which utilises NFC technology, is placed by the patient to continuously monitor glucose readings, as a useful component of any glucose management system.
Website: www.noviosense.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005032/en/
Contact information
NovioSense BV
Christopher Wilson
c.wilson@noviosense.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 16:00:00 EEST | Press release
Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligent Market Intelligence. “Boards are also increasingly viewing CEOs as a scarce global talent pool.” CEO turnover drives higher transition costs Cash sign-on bonuses for new S&P
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 16:00:00 EEST | Press release
Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by giving users a way to make the output from their AI tools visual, immediately editable, and accessible to the whole team on a shared canvas. Miro user data shows Claude
I-SEC Optimizes Airport Security Workforce Planning with Gurobi and Syntro29.9.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, and its partner Syntro, a provider of workforce scheduling solutions, are helping organizations like I-SEC, an international provider of airport security services, make better operational decisions in increasingly complex and highly regulated operating environments. As organizations face growing pressure to balance labor costs, regulatory requirements, service levels, and employee needs, many are turning to mathematical optimization to improve operational decision making. Airport security workforce planning is particularly complex, requiring organizations to align staffing levels with changing passenger volumes while adhering to strict regulations, accounting for required breaks and certifications, and ensuring coverage across multiple locations and checkpoints. Working with Syntro, I-SEC implemented a shift generator that leverages Gurobi’s solver. Rather than assigning employees directly to schedules, the solut
NTT DATA Launches ‘Intact, intelligent action.’ to Protect Fragile Places and Advance Sustainability Commitments29.9.2026 16:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced “Intact, intelligent action.” This global initiative is designed to help people and organizations translate sustainability commitments into meaningful action. The effort combines awareness, technology and stewardship in support of some of the world’s most treasured yet fragile places. Antarctica will be the first chapter. From November 25 to December 2, 2026, a dozen NTT DATA employees will join polar explorer Robert Swan and his 2041 Leadership on the Edge expedition aboard the Magellan Explorer. With the Antarctic Peninsula and nearby islands as their classroom, the NTT DATA team and more than 60 other business and community leaders will explore leadership under pressure, climate policy, sustainability and innovation with a focus on putting commitments into action. NTT DATA began working with Swan in 2022 and named him as the company’s Sustainability Ambassador in 2025. The expedition marks a 4
ACIC Equipment President Patrice Pelletier to Attend CPHI Milan 202629.9.2026 16:00:00 EEST | Press release
ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help customers move projects from molecule to market. At the heart of ACIC Equipment's offering is a carefully selected network of leading technology partners, combined with ACIC's integration expertise and North American commercial and technical support. Together, they give pharmaceutical manufacturers access to specialized technologies across radiopharmaceutical production, aseptic processing, sterilization and contamination control, formulation and pure-fluid systems, filling and inspection, freeze drying, cleanrooms, packaging, vacuu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom